December 4, 2017 | News & Notices Shimadzu, Fujitsu, and Fujitsu Laboratories Announce Results of Collaborative Research On the Path to Utilize AI in the Processing of Mass Spectrometry Measurement Data
Shimadzu Corporation, Fujitsu Limited, and Fujitsu Laboratories Ltd. are undertaking collaborative research*1 to develop technology that utilizes AI (artificial intelligence) to process the vast amounts of data used in analyzing the measurement results, which are essential to analytical processes, acquired from Shimadzu mass spectrometers.
Fujitsu, an information and communication technology company, has been exploring the creation of new businesses by using AI as an enabler of digital innovation. Shimadzu is an analytical equipment maker with customers who had voiced their hopes for automated, highly accurate analysis of complex data. Given that the aims of both companies matched, in November of last year they began collaborative research into AI for the automation of data analysis.
Mass spectrometers are used for research and quality control in various areas such as the establishment of early detection techniques for diseases and the measurement of residual pesticides in foods, and because of improvements in sensitivity and speed, the amount of data acquired is enormous. As a result, the data analysis step called "peak picking"*2 has become the bottleneck in the workflow. Complete automation is difficult and to some extent manual adjustments are required. Therefore, there are differences in analysis accuracy depending on each operator and there is a possibility that analytical results might be affected by each operator's practices and data alterations. In recent years, automated data analysis with high accuracy that eliminates this kind of dependence on individuals is now demanded in the fields of healthcare and new drug development.
To solve this issue using AI, the three companies investigated the application of deep learning, a neural network technology that imitates brain neurons. Arising to confront this process were two problems: 1) insufficient training data*3; and 2) learning could not proceed when analytical equipment output data was input, as is, into the deep learning network. In this collaborative research, Shimadzu developed technology to produce extra data to compensate for the lack of training data, and Fujitsu and Fujitsu Laboratories developed technology to convert the analysis equipment output features into images. Moreover, the companies developed the feature extraction technology to learn the analytical skills of experienced analysts. By doing this, the deep learning network was able to learn from the over 30,000 items of generated training data. Compared with manual peak picking results by an experienced operator, the automated peak picking results using AI had a false detection rate of 7% and an undetected rate of 9%*4. These results indicate that an automated peak picking can compare favorably with a peak picking by an experienced operator.
In the Shimadzu medium-term business plan that started in April 2017, strong emphasis is placed on the "Advanced Healthcare" area, aiming to create innovative products and services in the fields of prevention, diagnosis, treatment of disorders, and development of new drugs. This metabolomics research is also part of that initiative and is the first application to use the AI technology developed by the company. Metabolomics technology is used to investigate cells by detecting metabolites and following their behavior. The technology is expected to be used for unraveling physiological and pathological mechanisms and for exploring disease biomarkers.
Fujitsu has been developing AI for over 30 years, and introduced knowledge and technology based on this experience as "Fujitsu Human Centric AI Zinrai" in November 2015. Since then the company has implemented AI products and services for customers in a variety of fields. This time the company has turned its attention to metabolomics, a new application for deep learning, and plans to develop AI for the automation of data analysis.
Shimadzu and Fujitsu aim to integrate the AI systems developed in this collaboration into mass spectrometer software in 2018.
About Shimadzu Corporation
Since 1875, Shimadzu Corporation is pursuing leading-edge science and technologies in analytical and measuring instruments including chromatographs and mass spectrometers, medical devices, aeronautics, and industrial equipment. For more information, please see: https://www.shimadzu.com/
Fujitsu is the leading Japanese information and communication technology (ICT) company, offering a full range of technology products, solutions, and services. Approximately 155,000 Fujitsu people support customers in more than 100 countries. We use our experience and the power of ICT to shape the future of society with our customers. Fujitsu Limited (TSE: 6702) reported consolidated revenues of 4.5 trillion yen (US $40 billion) for the fiscal year ended March 31, 2017. For more information, please see http://www.fujitsu.com/.
About Fujitsu Laboratories
Founded in 1968 as a wholly owned subsidiary of Fujitsu Limited, Fujitsu Laboratories Ltd. is one of the premier research centers in the world. With a global network of laboratories in Japan, China, the United States and Europe, the organization conducts a wide range of basic and applied research in the areas of Next-generation Services, Computer Servers, Networks, Electronic Devices and Advanced Materials. For more information, please see: http://www.fujitsu.com/jp/group/labs/en/.
All company or product names mentioned herein are trademarks or registered trademarks of their respective owners. Information provided in this press release is accurate at time of publication and is subject to change without advance notice.